JP2022533418A5 - - Google Patents
Info
- Publication number
- JP2022533418A5 JP2022533418A5 JP2021569109A JP2021569109A JP2022533418A5 JP 2022533418 A5 JP2022533418 A5 JP 2022533418A5 JP 2021569109 A JP2021569109 A JP 2021569109A JP 2021569109 A JP2021569109 A JP 2021569109A JP 2022533418 A5 JP2022533418 A5 JP 2022533418A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- nos
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852039P | 2019-05-23 | 2019-05-23 | |
| US62/852,039 | 2019-05-23 | ||
| PCT/US2020/034281 WO2020237173A1 (en) | 2019-05-23 | 2020-05-22 | Anti-ror1/anti-cd3 bispecific binding molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533418A JP2022533418A (ja) | 2022-07-22 |
| JP2022533418A5 true JP2022533418A5 (enExample) | 2023-05-24 |
| JP7611171B2 JP7611171B2 (ja) | 2025-01-09 |
Family
ID=71078637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569109A Active JP7611171B2 (ja) | 2019-05-23 | 2020-05-22 | 抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220227866A1 (enExample) |
| EP (1) | EP3972999A1 (enExample) |
| JP (1) | JP7611171B2 (enExample) |
| KR (1) | KR20220012313A (enExample) |
| CN (1) | CN113874399B (enExample) |
| AU (1) | AU2020277489A1 (enExample) |
| BR (1) | BR112021023026A2 (enExample) |
| CA (1) | CA3139111A1 (enExample) |
| MX (1) | MX2021014193A (enExample) |
| TW (1) | TWI899079B (enExample) |
| WO (1) | WO2020237173A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4069735A1 (en) * | 2019-12-06 | 2022-10-12 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 bispecific antibody constructs |
| EP4100438A1 (en) * | 2020-02-07 | 2022-12-14 | Velosbio Inc. | Anti-ror1 antibodies and compositions |
| JP2024504471A (ja) * | 2021-02-02 | 2024-01-31 | ヌマブ セラピューティックス アーゲー | Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体 |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2023000791A1 (en) * | 2021-07-23 | 2023-01-26 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against ror1 and uses thereof |
| EP4413044A4 (en) * | 2021-10-07 | 2025-10-22 | Nat Res Council Canada | ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3803790B2 (ja) * | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| ES2702315T3 (es) * | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| WO2014163684A1 (en) * | 2013-04-03 | 2014-10-09 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| JP2016538275A (ja) * | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
| JP6871155B2 (ja) * | 2014-07-25 | 2021-05-12 | メモリアル スローン ケタリング キャンサー センター | 二重特異性ｈｅｒ２及びｃｄ３結合分子 |
| EP3204415B1 (en) * | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3091032A1 (en) * | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for cd3 |
| MA55746A (fr) * | 2016-01-21 | 2022-03-02 | Novartis Ag | Molécules multispécifiques ciblant cll-1 |
| TW201734049A (zh) * | 2016-01-22 | 2017-10-01 | 健生生物科技公司 | 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法 |
| WO2017142928A1 (en) | 2016-02-17 | 2017-08-24 | Macrogenics, Inc. | Ror1-binding molecules, and methods of use thereof |
| US20190336615A1 (en) * | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| AU2018289581C1 (en) * | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| EP4100438A1 (en) * | 2020-02-07 | 2022-12-14 | Velosbio Inc. | Anti-ror1 antibodies and compositions |
-
2020
- 2020-05-22 TW TW109117258A patent/TWI899079B/zh active
- 2020-05-22 US US17/613,251 patent/US20220227866A1/en active Pending
- 2020-05-22 CN CN202080038180.6A patent/CN113874399B/zh active Active
- 2020-05-22 EP EP20732061.5A patent/EP3972999A1/en active Pending
- 2020-05-22 AU AU2020277489A patent/AU2020277489A1/en active Pending
- 2020-05-22 MX MX2021014193A patent/MX2021014193A/es unknown
- 2020-05-22 CA CA3139111A patent/CA3139111A1/en active Pending
- 2020-05-22 JP JP2021569109A patent/JP7611171B2/ja active Active
- 2020-05-22 KR KR1020217041982A patent/KR20220012313A/ko not_active Withdrawn
- 2020-05-22 WO PCT/US2020/034281 patent/WO2020237173A1/en not_active Ceased
- 2020-05-22 BR BR112021023026A patent/BR112021023026A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533418A5 (enExample) | ||
| JP7464764B2 (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| CN109071666B (zh) | 人脊髓灰质炎病毒受体(pvr)特异性抗体 | |
| US10519236B2 (en) | Antibodies specific to delta 1 chain of T cell receptor | |
| JP2020530263A5 (enExample) | ||
| JP2022526764A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| WO2019214624A1 (en) | Fully human antibodies against ox40, method for preparing same, and use thereof | |
| ME02377B (me) | Anti-igf antitijela | |
| JP7692422B2 (ja) | 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用 | |
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2023518153A5 (enExample) | ||
| JP2022532991A5 (enExample) | ||
| CN115197325A (zh) | 抗体在抗肿瘤治疗中的用途 | |
| CN115210261A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| JP2025513721A5 (enExample) | ||
| JP2022550327A (ja) | 新規の抗ｐｄ－ｌ１抗体 | |
| WO2021057930A1 (en) | A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof | |
| US20240270865A1 (en) | Cancer treatment methods using anti-cd73 antibodies | |
| JP2021516670A (ja) | 抗ｔｒａｉｌｒ２抗体−毒素−複合体およびその抗腫瘍治療における薬物用途 | |
| WO2021169986A1 (en) | A bifunctional fusion protein and uses thereof | |
| JP7196311B2 (ja) | 抗ｔｉｍ－３抗体とその利用 | |
| CN107106676A (zh) | 用于治疗肉瘤的组合物和方法 | |
| RU2021137832A (ru) | Анти-ror1/анти-cd3 биспецифические связывающие молекулы | |
| CN118047867B (zh) | 一种抗bcma的纳米抗体、抗体及其应用 |